Marks Rebecca A, Koch Michael O, Lopez-Beltran Antonio, Montironi Rodolfo, Juliar Beth E, Cheng Liang
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Hum Pathol. 2007 Aug;38(8):1207-11. doi: 10.1016/j.humpath.2007.01.006. Epub 2007 May 8.
The presence of positive surgical margins is a negative prognostic indicator in patients undergoing prostatectomy for prostate cancer; whether the extent of the positive margins affects the clinical outcome with regards to prostate-specific antigen (PSA) recurrence remains uncertain. We evaluated the linear extent of margin positivity as a prognostic indicator in a series of radical prostatectomy specimens. One hundred seventy-four consecutive margin-positive prostatectomy specimens were evaluated. The linear extent of margin positivity was measured with an ocular micrometer and ranged from 0.05 to 75.0 mm (mean, 8.94; median, 5.0). The linear extent of margin positivity was associated with tumor volume (P = .03) but was not associated with patients' age at surgery, preoperative PSA level, prostate weight, pathologic stage, Gleason score, extraprostatic extension, seminal vesicle invasion, perineural invasion, high-grade prostatic intraepithelial neoplasia, or PSA recurrence. In the full model multiple Cox regression, significant predictors for PSA recurrence were Gleason score (P = .001) and preoperative PSA (P = .01); extent of margin positivity was not predictive of PSA recurrence (hazard ratio, 1.00; 95% confidence interval, 0.98-1.02; P = .97) nor was tumor volume a significant factor when adjusted for other covariates (P = .27). Preoperative PSA, tumor stage, and Gleason score remained significant prognostic factors in evaluating the likelihood of PSA recurrence in patients with positive surgical margins; the extent of margin positivity, however, is not a prognostic factor for PSA recurrence and should, therefore, not necessarily be included in the final report for radical prostatectomy specimens.
对于接受前列腺癌前列腺切除术的患者,手术切缘阳性是一个不良预后指标;切缘阳性的范围是否会影响前列腺特异性抗原(PSA)复发的临床结局仍不确定。我们评估了一系列根治性前列腺切除标本中切缘阳性的线性范围作为预后指标。对174例连续的切缘阳性前列腺切除标本进行了评估。用目镜测微计测量切缘阳性的线性范围,范围为0.05至75.0毫米(平均8.94;中位数5.0)。切缘阳性的线性范围与肿瘤体积相关(P = 0.03),但与患者手术时年龄、术前PSA水平、前列腺重量、病理分期、Gleason评分、前列腺外侵犯、精囊侵犯、神经周围侵犯、高级别前列腺上皮内瘤变或PSA复发无关。在全模型多因素Cox回归中,PSA复发的显著预测因素是Gleason评分(P = 0.001)和术前PSA(P = 0.01);切缘阳性范围不能预测PSA复发(风险比,1.00;95%置信区间,0.98 - 1.02;P = 0.97),调整其他协变量后肿瘤体积也不是显著因素(P = 0.27)。术前PSA、肿瘤分期和Gleason评分仍然是评估手术切缘阳性患者PSA复发可能性的重要预后因素;然而,切缘阳性范围不是PSA复发的预后因素,因此不一定应包含在根治性前列腺切除标本的最终报告中。